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Abstract
Backgound: The neurobiological changes underlying depression resistant to treatments remain poorly understood, and 
failure to respond to selective serotonin reuptake inhibitors may result from abnormalities of neurotransmitter systems that 
excite serotonergic neurons, such as histamine.
Methods: Using behavioral (tail suspension test) and neurochemical (in vivo microdialysis, Western-blot analysis) approaches, 
here we report that antidepressant responses to selective serotonin reuptake inhibitors (citalopram or paroxetine) are 
abolished in mice unable to synthesize histamine due to either targeted disruption of histidine decarboxylase gene (HDC-/-) 
or injection of alpha-fluoromethylhistidine, a suicide inhibitor of this enzyme.
Results: In the tail suspension test, all classes of antidepressants tested reduced the immobility time of controls. Systemic 
reboxetine or imipramine reduced the immobility time of histamine-deprived mice as well, whereas selective serotonin 
reuptake inhibitors did not even though their serotonergic system is functional. In in vivo microdialysis experiments, 
citalopram significantly increased histamine extraneuronal levels in the cortex of freely moving mice, and methysergide, a 
serotonin 5-HT1/5-HT2 receptor antagonist, abolished this effect, thus suggesting the involvement of endogenous serotonin. 
CREB phosphorylation, which is implicated in the molecular mechanisms of antidepressant treatment, was abolished in 
histamine-deficient mice treated with citalopram. The CREB pathway is not impaired in HDC-/- mice, as administration of 
8-bromoadenosine 3’, 5’-cyclic monophosphate increased CREB phosphorylation, and in the tail suspension test it significantly 
reduced the time spent immobile by mice of both genotypes.
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Conclusions: Our results demonstrate that selective serotonin reuptake inhibitors selectively require the integrity of the 
brain histamine system to exert their preclinical responses.
Keywords: Histidine decarboxylase, citalopram, reboxetin, CREB, tail suspension test, in vivo microdialysis
Introduction
Major depression is a common psychiatric disorder with a dev-
astating socio-economic impact worldwide (Gustavsson et  al., 
2011). First-line treatments include selective serotonin reuptake 
inhibitors (SSRIs), yet fewer than 50% of patients respond ade-
quately to medication (Berton and Nestler, 2006a). SSRI ineffi-
cacy may result from abnormalities of neurotransmitter systems 
that excite serotonergic neurons (Coplan et al., 2014). Histamine 
is synthesized from histidine by histidine-decarboxylase (HDC) 
(Haas et al., 2008) in neurons restricted to the hypothalamic tub-
eromamillary nucleus (TMN) and innervating most of the brain, 
including the raphe nuclei (Watanabe et al., 1983). Experimental 
studies demonstrated functional interactions between histamin-
ergic and serotonergic systems (Airaksinen et al., 1989; Laitinen 
et  al., 1995; Brown et  al., 2002) that share control of functions 
impaired in depression, such as appetite, cognition, emotion, and 
sleep (Passani et al., 2004; Haas et al., 2008). Histamine H1-receptor 
activation increased the firing rate of serotonergic neurons 
(Eriksson et al., 2001). Interestingly, PET studies showed reduced 
H1-receptor density in the brain of depressed patients that posi-
tively correlated with the severity of clinical profile (Kano et al., 
2004; Yanai and Tashiro, 2007). Here, we report that behavioral and 
neurochemical responses to SSRIs exclusively, and not to other 
antidepressants, are abolished in mice genetically or pharmaco-
logically unable to synthesize histamine. Disruption of histamine 
neurotransmission affected not only behavioral responses but 
also the activation of intracellular pathways elicited by SSRIs. To 
this end, we used HDC-/- mice, their HDC+/+ littermates, CD1 mice 
acutely deprived of histamine by injecting intracerebroventricu-
lar (i.c.v.) alpha-fluoromethylhistidine (α-FMHis), a suicide inhibi-
tor of HDC (Garbarg et  al., 1980), and sham-operated controls. 
Hence, using different experimental approaches, we demonstrate 
that histaminergic neurotransmission affects responses to SSRIs.
Methods
Chemicals
Citalopram hydrobromide (Tocris), reboxetine mesylate (Tocris), 
paroxetine hydrochloride hemihydrate (Sigma), imipramine 
hydrochloride (Sigma), and methysergide (Sigma) were freshly 
dissolved into saline (NaCl 0.9%) before use. Compounds were 
dissolved in a final volume of 10 mL/kg. α-FMHis (synthesized at 
Abbott Laboratories, Chicago, IL) was injected i.c.v. at the dose of 
5 µg dissolved in 5 µL of saline. All doses were calculated as mg/
kg of the free base. Control animals received saline. In reverse 
dialysis experiments, drugs were diluted in the perfusing 
Ringer’s solution. All other reagents and solvents were of high 
performance liquid chromatography (HPLC) grade or the highest 
grade available (Sigma).
Animals
All animals were housed in macrolon cages in temperature-con-
trolled rooms (20–24°C), allowed free access to food and water, 
and kept on a 12-h-light/-dark cycle (light started at 7:00 am). Male 
CD-1 mice (25–30 g body weight, Harlan, Italy) were used along 
with female and male inbred HDC+/+ and HDC-/- mice of 11 to 13 
weeks of age and 25 to 30 mg body weight bred in the Centre for 
Laboratory Animals, Universitá di Firenze, Italy, and housed in 
a dedicated room. They were descendants of the 129/Sv mouse 
strain generated by Ohtsu (Ohtsu et  al., 2001). Their genotype 
with regards to the HDC gene was determined according to the 
polymerase chain reaction (PCR) protocol described by Parmentier 
(Parmentier et al., 2002). All the experiments were performed in 
strict compliance with the EEC recommendations for the care and 
use of laboratory animals (2010/63/EU) and were approved by the 
Animal Care Committee of the Dipartimento di Neuroscienze, 
Psicologia, Area del Farmaco e Salute del Bambino, Sezione di 
Farmacologia e Tossicologia, Universitá di Firenze, Italy. Ethical 
policy of the University of Florence complies with the Guide for the 
Care and Use of Laboratory Animals of the US National Institutes 
of Health (NIH publication no. 85-23, revised 1996; University of 
Florence assurance number: A5278-01). Every effort was made to 
minimize animal suffering and to reduce the number of animals 
used. Animals were handled for at least 4 days before experiments 
begun to become acclimatized to human contact.
Tail Suspension Test
tail suspension test (TST) was carried out as described (Steru 
et  al., 1985). Briefly, 30 minutes after i.p. injection of saline or 
drugs, mice were individually suspended by the tail to a hori-
zontal ring stand bar (distance from floor = 30 cm) using adhesive 
tape (distance from tip of tail = 2 cm). Typically, mice demon-
strated several escape-oriented behaviors interspersed with 
temporally increasing bouts of immobility. A 4-minute test ses-
sion was scored by a trained observer who was unaware of the 
treatment and/or genotype. The parameter recorded was the 
number of seconds spent immobile. All experimental testing 
sessions were conducted between 9:00 am and 2:00 pm, with ani-
mals randomly assigned to treatment conditions and tested in 
counterbalanced order. In subchronic treatment, citalopram was 
injected i.p. at a dose of 10 mg/kg at 23.5, 5, and 1 hour for a total 
of 3 doses (30 mg/kg/24 h) before exposure to TST. Control ani-
mals were injected with 0.9% saline following the same schedule.
Surgical Procedures
Mice anesthetized with 5% isoflurane in humidified O2 and 
positioned in a stereotaxic frame (Stellar; Stoelting Co., Wood 
Dale, IL) were implanted with one guide cannula (CMA/7, CMA 
Microdialysis). Each mouse was implanted with one guide 
cannula according to the following coordinates from bregma 
(Paxinos and Franklin, 1997): cortex, AP = +2.1, L = -1.0, DV = -1.5; 
hippocampus, AP = -3.0, L = +3.0, DV = -1.8. A  surgical screw 
served as an anchor, and the cannulae were fixed to the skull 
with acrylic dental cement.
α-FMHis i.c.v. Infusion
Mice were anesthetized as above and placed on a stereotaxic 
frame (Kopf Instruments). A  stainless-steel cannula (7 mm in 
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length, outer diameter 0.5 mm, and inner diamter 0.25 mm) was 
implanted in the lateral ventricle and fixed to the skull using 
dental cement. The following coordinates were used according 
to the mouse brain atlas (Franklin and Paxinos, 2007): AP -0.3; L 
±1; DV -1. After 7 days of recovery, α-FMH was infused into ven-
tricle. A  stainless-steel injection micro-needle was connected 
through a polyethylene catheter to a 1000-µL Hamilton preci-
sion syringe and then lowered into the lateral cerebral ventricle 
(dorsoventral, DV 2.4 mm). α-FMHis was delivered via an infu-
sion pump (5 µL) within 5 minutes. After infusion, the needle 
was left in place for an additional minute.
Microdialysis Experiments
Microdialysis was performed 48 hours after surgery, during 
which mice recovered from surgery, housed one per cage. The 
stylet was removed from the guide cannulae, and the micro-
dialysis probes (CMA/7 7/2 Cuprofane; molecular mass cutoff 
6000 Da; CMA Microdialysis) were inserted; the dialyzing mem-
brane protruded 2 mm from the tip of the cannula. Probes were 
perfused with Ringer’s solution (147 mM NaCl, 2.4 mM CaCl2, 
and 4.0 mM KCl, pH 7.0) at a flow rate of 1  µL/min by use of 
a microperfusion pump (Mod CMA/100; Carnegie Medicine, 
Stockholm, Sweden). Two hours after insertion of the microdi-
alysis probes, when neurotransmitter release became stable, 
collection of 30-minute fractions was started. Spontaneous 
release was defined as the average value of the first three/four 
30-minute fractions collected during 90/120 minutes of perfu-
sion with Ringer’s solution before drug treatment. All subse-
quent fractions were expressed as percentage increase of this 
value. Drug addition to the perfusion fluid did not modify the 
pH of the medium. Histaminergic neurons are more active dur-
ing wakefulness, their activity being lowest during quiet wak-
ing and highest during attentive waking (Takahashi et al., 2006). 
In the present study, the experiments were performed during 
the light phase, and histaminergic cell activity was presum-
ably low. Accordingly, most of the mice (about 90%) were sleep-
ing for the entire period preceding citalopram administration 
that produced weak signs of awakening but not of agitation or 
irritability.
Determination of HA
To prevent degradation of histamine (HA), 1.5 µL of 5 mM HCl 
was added to each sample. The dialysates were kept at -80°C 
until analysis. HA contents in the dialysates were determined 
by HPLC-fluorometry (Cenni et  al., 2006). In brief, the column 
(Hypersil ODS, 3  µm, 2.1 × 100 mm; Thermo Fisher Scientific, 
Waltham, MA) was eluted with 0.25 M potassium dihydrogen 
phosphate containing 5% octanesulfonic acid (Sigma-Aldrich, 
St. Louis, MO) at a flow rate of 0.4 mL/min. The eluate from the 
column was mixed first with 0.1% o-phthalaldehyde solution 
at a flow rate of 0.1 mL/min and then to a solution containing 
4 M sodium hydroxide and 0.2 M boric acid (flow rate, 0.137 mL/
min) to adjust the reaction mixture to pH 12.5. The reaction 
took place at 45°C. Then 17% orthophosphoric acid was added 
to the solution (flow rate, 0.137 mL/min) to reach a final reaction 
mixture at pH 3. The fluorescent intensity was measured with a 
spectrofluorometer (series 1100; Agilent, Waldbronn, Germany) 
at 450 nm with excitation at 360 nm. The sensitivity limit was 
10 fmol and the signal/noise ratio was higher than 3. HA levels 
in the dialysate samples were calculated as fmol/30 min. In α-
FMHis–treated mice, HA levels were below the detection sensi-
tivity limits of the apparatus.
Determination of 5-HT, NA, and DA
The dialysates were kept at -80°C until analysis. HPLC was per-
formed as described (Cassano et  al., 2009). Briefly, the endog-
enous levels of dopamine (DA), noradrenaline (NA), and 5-HT 
were assayed by microbore HPLC using a SphereClone 150-
mm × 2-mm column (3-µm packing). Detection was accomplished 
with a Unijet cell (BAS) with a 6-mm-diameter glassy carbon elec-
trode at +650 mV vs an Ag/AgCl reference electrode connected 
to an electrochemical amperometric detector (INTRO, Antec 
Leyden, Netherlands). The chromatographic conditions were: (1) 
a mobile phase composed of 85 mM of sodium acetate, 0.34 mM 
Ethylenediaminetetraacetic acid (EDTA), 15 mM sodium chloride, 
0.81 mM of octanesulphonic acid sodium salt, 5% methanol (vol/
vol), pH = 4.85; (2) a rate flow of 220 µL/min; and (3) a total runt-
ime of 65 minutes. For each analysis, a set of standards contain-
ing various concentrations of each compound (monoamines and 
metabolites) was prepared in the acid solution and was injected 
before, and at the end, of any one run to account for changes 
in chromatographic conditions during the run. The calibration 
curves were calculated by linear regression using the mean of the 
standard values before and after the run. The retention times of 
standards were used to identify peaks, and peak areas were used 
to quantify neurotransmitters levels, calculated as fmol/30 min.
Histology
The placement of microdialysis membranes was verified post-
mortem. Mice were overdosed with chloral hydrate and the 
brains removed and stored in 10% formalin for 10 days. Forty-
micrometer sections were then sliced on a cryostat, mounted 
on gelatin-coated slides, and stained with cresyl violet for light 
microscopic observation. Data from mice in which the mem-
branes were not correctly positioned were discarded (<5%).
8-OH-DPAT–Induced Hypothermia
Body temperature was measured with a digital thermom-
eter (TH5 Thermalert monitoring thermometer, Physitemp 
Instruments) equipped with a probe for mice (RET-3) inserted 
1.0 cm into the rectum. All temperatures were measured at 
ambient temperature (23 ± 1°C). Basal temperature was meas-
ured 30 minutes and immediately prior to the subcutaneous 
(s.c.) injection of 8-hydroxy-2-(di-n-propylamino)tetralin hydro-
bromide (8-OH-DPAT; 1 mg/kg, dissolved in 0.1 mL saline). Body 
temperature was recorded every 15 minutes for 1 hour after 
injection.
Western-Blotting Analysis
Hippocampi were homogenized in 0.2 mL ice-cold lysis 
buffer (50 mM Tris, pH 7.5, 50 mM NaCl, 10 mM ethylene glycol 
tetraacetic acid, 5 mM Ethylenediaminetetraacetic acid, 2 mM 
SodiumPyrophosphate, 4 mM Para-Nitrophenylphosphate, 1 mM 
Na3VO4, 1.1 mM Phenyl-methyl-sulphonyl fluoride, 20 µg/µL leu-
peptin, 50  µg/µL aprotinin, 0.1% SDS) using a pestle, sonicated 
briefly, and centrifugated at 12 000 rpm at 4°C for 15 minutes. 
The supernatant was collected and protein concentration was 
determined by Pierce BSA (Thermo Scientific). Samples were 
diluted in a mix of lysis buffer and loading buffer 2× (50 mM Tris, 
pH 6.8, 100 mM DL-dithiotheitol (DTT), 10% glycerol, 1% bromo-
phenol blue, and 2% sodium dodecyl sulphate (SDS)) and boiled 
for 10 minutes at 95°C. Aliquots containing 40 µg total proteins 
were separated on 8% (SDS)-polyacrylamide gel electrophore-
sis and transferred to polyvinylidene difluoride membranes 
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(Immobilon Transfer Membranes, Millipore). Blots were blocked 
in Tris-buffered saline, pH 7.6, containing 0.1% of Tween 20 (TBS-
T) and 5% skimmed milk (Bio-Rad Laboratories) for 2 hours at 
room temperature and then incubated overnight, on different 
days, with monoclonal antibodies against phospho-CREB (pCREB-
Ser133) (1:1000, catalogue no. 9198) and CREB (1:1000, catalogue 
no. 9197, both from Cell Signaling Technology), which were dis-
solved in TBS-T with 5% bovine serum albumin. Membranes were 
then washed 3 times with TBS-T and incubated for 120 minutes 
at room temperature in TBS-T with 1% skimmed milk containing 
anti-rabbit peroxidase-conjugated secondary antibody (1:5000, 
catalogue no. 7074, Cell Signaling Technology). After washing in 
TBS-T 3 times, enhanced chemiluminescence reaction (Luminata 
Crescendo, Millipore) was used to visualize the peroxidase-coated 
bands. The bands were quantified by densitometry analysis using 
an ImageQuant 350 imager and ImageQuant TL software (Perkin 
Elmer). pCREB densities were divided by their respective CREB 
densities within each sample to obtain pCREB:CREB ratio values 
and were averaged for each treatment group.
Statistical Analysis
All values are expressed as means ± SEM, and the number of ani-
mals used in each experiment is indicated. Data were analyzed 
using 1-way ANOVA and Neuman-Keuls multiple comparison 
test or Scheffe’s test, unless otherwise stated, using the software 
GraphPad Prism. The level of significance was set at P ≤ .05. Data 
of the microdialysis experiments were analysed using a 2-way 
ANOVA and Bonferroni’s test.
Results
Effects of Various Antidepressants in the TST
We first evaluated the effect of 2 SSRIs, citalopram and par-
oxetine (Bezchlibnyk-Butler et  al., 2000), on the TST, a widely 
used paradigm for assessing antidepressant activity (Steru 
et al., 1985), in HDC-/- mice and littermates. The TST is a com-
mon model of stress-induced behavioral depression, and all 
major classes of antidepressants effectively reduce immobility 
in this test, confirming its validity as a drug-screening para-
digm (Cryan et al., 2005). There was no significant difference of 
immobility time between saline-treated HDC+/+ and HDC-/- mice 
(Figure 1). Intraperitoneal administration of citalopram signifi-
cantly decreased immobility of male HDC+/+ (1-way ANOVA and 
Neuman-Keuls multiple comparison test, F3,54 = 13.948; P < .0001; 
Figure 1a) and female (F5,65 = 6.1; P < .0001; Figure 1b) mice, whereas 
no significant effects were observed in HDC-/- mice of either 
gender. Paroxetine reduced immobility of HDC+/+ (F3,38 = 7.824, 
P < .0001), whereas it was ineffective in HDC-/- mice (Figure 1c). 
Different responses are reported after acute or repeated citalo-
pram administration (Mombereau et al., 2010). In our paradigm, 
3 administrations of citalopram during 24 hours significantly 
reduced immobility of HDC+/+ mice (F3,44 = 9.236, P < .0001) but not 
of their HDC-/- littermates in a comparable fashion with single 
administrations (Figure 1d).
To test whether absence of response to SSRIs correlates with 
the selectivity to inhibit 5-HT reuptake, HDC+/+ and HDC-/- mice 
received i.p. injections of imipramine or reboxetine, 2 antide-
pressants that block NA reuptake (Wong et al., 2000; Hajós et al., 
2004). Imipramine significantly decreased immobility of both 
genotypes (F3,44 = 43.217, P < .0001; Figure 1e), as well as reboxe-
tine (males: F4,54 = 12.172, P < .0001; Figure 1f; females: F4,55 = 7.199, 
P < .0001; Figure 1g) compared with saline-treated controls.
Functional Integrity of the Serotonergic System
We checked the functional integrity of the serotonergic trans-
mission in HDC-/- mice performing in vivo microdialysis 
experiments. Perfusion of the dorsal hippocampus with 50 µM 
citalopram significantly increased 5-HT extraneuronal levels 
with similar magnitude in both HDC+/+ (F9,70 = 13.08; P < .0001) 
and HDC-/- (F9,70 = 9.67; P < .0001) mice, leaving DA and NA release 
unchanged (Figure 2). Moreover, since desensitization of 5-HT1A 
autoreceptors presumably plays a key role in the therapeutic 
action of SSRIs (Piñeyro and Blier, 1999), whereas their upregula-
tion could be related to core symptoms of depression (Stockmeier 
et al., 1998), we checked the functional integrity of the seroton-
ergic transmission in HDC-/- mice also by using the hypothermic 
response to the 5-HT1A agonist 8-OH-DPAT. 5-HT1A autoreceptors 
in raphe neurons participate in the control of central seroton-
ergic tone by mediating a negative feedback regulation of neu-
ronal firing. 8-OH-DPAT–induced hypothermia appears related 
to activation of 5-HT1A autoreceptors and decreased 5-HT 
release (Goodwin et al., 1985b) and hence provides a valid meas-
ure of the functional status of 5-HT1A autoreceptors (Alexandre 
et al., 2006). Subcutaneous injections of 8-OH-DPAT induced sig-
nificant decreases of body temperature that were equivalent in 
HDC+/+ and HDC-/- mice (F5,115 = 57.06; P < .0001) (Figure 3). A single 
administration of citalopram 30 minutes prior to 8-OH-DPAT 
significantly attenuated 8-OH-DPAT–induced hypothermia in 
both genotypes (F3,115 = 14,85; P < .0001) without affecting basal 
temperature (Figure 3).
Influence of Acute HA Depletion on Antidepressant 
Effects in the TST
As the findings in HDC-/- mice may be hindered by compen-
satory mechanisms, we investigated the effects of citalo-
pram and reboxetine in CD-1 mice depleted of HA, by i.c.v. 
injection of α-FMHis, an irreversible HDC inhibitor, that 
completely suppressed spontaneous and citalopram-evoked 
HA cortical release (Figure 5). Effects on TST were examined 
before and after i.c.v. injection of α-FMHis in the same mice 
according to the protocol shown in Figure  4a. Mice were 
divided into 7 groups run simultaneously and exposed to 
TST on day 1 (D1) and day 8 (D8) after different treatment 
combinations. Naive mice received no treatment. On D1, 2 
groups received i.p. saline injections, 2 groups citalopram, 
and 2 groups reboxetine 30 minutes before TST (Figure 4b). 
On D7, one saline group received an i.c.v. saline injection, 
the other an i.c.v. injection of α-FMHis. The same pattern 
was applied to mice treated with citalopram or reboxetine 
on D1 (Figure 4b). On D8 and 30 minutes before TST, D1 saline 
groups received saline i.p. injections, D1 citalopram-treated 
mice i.p. injections of citalopram, and D1 reboxetine-treated 
mice i.p. injections of reboxetine. ANOVA revealed a sig-
nificant treatment effect (F13,116 = 22.101, P < .0001). Scheffe’s 
posthoc analysis showed that citalopram- or reboxetine-
treated mice on D1 spent significantly less time immobile 
than corresponding control groups (saline-treated and 
naive mice on D1, P < .05-0.01) (Figure  4b). Mice responded 
to reboxetine in a similar fashion on D1 and D8 indepen-
dently of saline or α-FMHis treatment on D7. However, mice 
receiving α-FMHis on D7 and citalopram on D8 spent sig-
nificantly more time immobile than on D1 (P < .01) and more 
than those receiving i.c.v. saline on D7 (P < .01), indicating 
that they became insensitive to the behavioral effects of cit-
alopram (Figure 4b).
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Functional Interactions between the Serotonergic 
and Histaminergic Systems
Prompted by our behavioral results, we investigated the func-
tional interaction between the serotonergic and histamin-
ergic systems. We first tested the effect of citalopram on HA 
extraneuronal levels in the cortex of freely moving CD1 mice. 
Citalopram significantly increased HA extraneuronal levels 
immediately after its administration, up to a peak value of 
75 ± 14% (F9,59 = 26.12; P < .0001) (Figure 5). Mean basal extraneu-
ronal levels were 75 ± 10 fmol/30 min (n = 4). We then deter-
mined if endogenous 5-HT is involved in citalopram-evoked 
increase of HA extraneuronal levels. Methysergide, a 5-HT2A/2c 
receptor antagonist (Martin and Sanders-Bush, 1982), given 
i.p. 30 minutes before citalopram fully antagonized citalopram-
elicited increase of HA extraneuronal levels (Figure  5). The 
mean basal extraneuronal level of HA was 66 ± 7 fmol/30 min 
(n = 6). In another set of experiments, 10 µM methysergide was 
included in the cortical perfusion medium 30 minutes before 
citalopram and maintained for 120 minutes. Local administra-
tion of methysergide did not affect citalopram-elicited increase 
of HA extraneuronal levels (peak value of 92 ± 7%; F9,39 = 26.08; 
P < .0001) (Figure  5). The mean extraneuronal level of HA was 
72 ± 11 fmol/30 min (n = 3). Two-way ANOVA revealed a significant 
effect of treatment interactions (F18,102 = 5.1; P < .0001). Posthoc 
analysis revealed that systemic but not local treatment with 
methysergide significantly the citalopram-elicited increase 
of HA extraneuronal levels. In α-FMHis–treated mice, basal 
HA extraneuronal levels were below the detection sensitivity 
(Figure  5). In these animals, citalopram failed to increase HA 
extraneuronal levels above the detection sensitivity (Figure 5).
Figure 1. Behavioral effects of antidepressants in mice genetically deprived of histamine (HA). The selective serotonin reuptake inhibitors (SSRIs) citalopram (A, males; 
B, female) and paroxetine (C) reduced immobility time of HDC+/+ but not of HDC-/- mice. Three citalopram injections within 24 hours reduced immobility time only in 
HDC+/+ mice (D). The tricyclic antidepressant (TCA) imipramine decreased immobility time of both genotypes (E). The Serotonin–norepinephrine reuptake inhibitor 
(SNRI) reboxetine reduced immobility time in males (F) and females (G) of both genotypes. Shown are means ± SEM of 8 to 18 mice/group. **P < .01, ***P < .001 vs saline-
treated mice of the corresponding genotype (ANOVA and Neuman-Keuls multiple comparison test). Saline-treated mice of both genotypes and genders showed no 
differences in immobility in all experiments.
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CREB Phosphorylation in the Hippocampus of HDC+/+ 
and in HDC-/- Mice
Correlation between SSRIs administration and increases in 
CREB phosphorylation in the hippocampus supports CREB’s role 
in mediating antidepressant effects and suggests the hippocam-
pus as an important neural substrate mediating antidepressant 
responses (Berton and Nestler, 2006b; Blendy, 2006; Mombereau 
et al., 2010). Three injections of citalopram during 24 hours, suf-
ficient to induce long-lasting adaptations produced by chronic 
administration of antidepressants (Conti et al., 2002; Gur et al., 
2007), significantly increased pCREB in the hippocampus of 
HDC+/+ but not of HDC-/- mice compared with saline-treated 
animals of the same genotype (F3,28 = 4.89, P < .05) (Figure  6a). 
Phosphorylation of CREB is initiated by cAMP-dependent protein 
kinase. To investigate the integrity of this pathway, we treated 
HDC+/+ and HDC-/- mice with 8-bromoadenosine 3’, 5’-cyclic 
monophosphate (8-Br-cAMP), a long-acting activator of protein 
kinase. I.c.v. administration of 8-Br-cAMP (5 µg/5 µL, 30 minutes 
prior to sacrifice) increased pCREB in the hippocampus of mice 
of both genotypes (F3,15 = 6.301; P < .05) (Figure 6b). Furthermore, 
8-Br-cAMP significantly reduced the immobility time of mice 
of both genotypes (F3,32 = 9.896, P < .05) compared with saline-
injected controls in the TST (Figure  6c). These results clearly 
indicate that CREB intracellular machinery is not impaired in 
HDC-/- mice.
Discussion
The present study provides strong evidence that intact HA 
neurotransmission is required specifically for the SSRIs cit-
alopram and paroxetine to reduce immobility in the TST. 
Figure 2. Effects of citalopram on hippocampal extraneuronal levels of 5-HT, dopamine (DA), and noradrenaline (NA) from hippocampi of HDC+/+ and HDC-/- mice. (A) 
Neurotransmitter extraneuronal levels were measured in fractions collected every 30 minutes. Baseline values were determined from the average of 4 samples preced-
ing citalopram infusion, which was begun at time 120 and terminated at time 180. No significant differences were observed between HDC+/+ and HDC-/- mice. Citalopram 
significantly increased the extraneuronal levels of 5-HT in the hippocampus of both genotypes, but not of DA or NA. The mean basal extraneuronal level of 5-HT was 
69 ± 15 fmol/30 min in HDC-/- mice (n = 8) and 77 ± 11 fmol/30 min in HDC+/+ mice (n = 8). The mean of the DA basal extraneuronal level was 68 ± 5 fmol/30 min in HDC-/- mice 
(n = 6) and 67 ± 7 fmol/30 min in HDC+/+ mice (n = 6). The mean of the NA extraneuronal level was 17 ± 5 fmol/30 min in HDC-/- mice (n = 6) and 15 ± 5 fmol/30 min in HDC+/+ 
mice (n = 6). Represented are means ± SEM of 6 to 8 mice. ***P < .001 from “citalopram” and “cortical methysergide + citalopram” (2-way ANOVA and Bonferroni test).
Figure 3. Effects of citalopram on hypothermic response induced by 8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT) in HDC+/+ and HDC-/- mice. 
8-OH-DPAT (1 mg/kg, s.c.) similarly decreased body temperature in HDC+/+ and HDC-/- mice. A single administration of citalopram 30 minutes prior to 8-OH-DPAT injection 
attenuated hypothermic response elicited by the prototypical agonist in both genotypes. Moreover, citalopram failed to affect basal temperature. Represented are means 
± SEM of 6 to 7 mice. ***P < .001 from basal temperature of the same group; #P < .05, ##P < .01 from saline of corresponding genotype (2-way ANOVA and Bonferroni test).
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All antidepressants effectively reduce immobility in this test 
(Lucki et  al., 2001). Antidepressants of other classes, such as 
imipramine (tricyclic) or reboxetine (selective NA reuptake 
inhibitor), were equally effective at reducing immobility in mice 
with or without HA. Low levels of 5-HT may cause insensitiv-
ity to SSRIs in the TST (O’Leary et al., 2007). This is not the case 
for HDC-/- mice, since citalopram induced comparable increases 
of 5-HT extraneuronal levels in the hippocampus of HDC-/- and 
HDC+/+ mice. In addition, citalopram application did not increase 
DA or NA extraneuronal levels, confirming its selectivity for 5-HT 
transporters (Millan et al., 2001). Desensitization of the 5-HT1A 
receptor is thought to mediate at least in part the therapeutic 
efficacy of SSRIs (Gray et al., 2013). The normal functioning of 
this receptor can be assessed by measuring the hypothermic 
response elicited by 8-OH-DPAT, a 5-HT1A agonist (Hjorth, 1985; 
Seletti et al., 1995; Evrard et al., 2002). 8-OH-DPAT–induced hypo-
thermia is presumably related to a drop in extracellular levels 
of 5-HT mediated by somatodendritic 5-HT1A autoreceptors in 
the raphe (Goodwin et al., 1985a). The hypothermic response to 
8-OH-DPAT was equivalent in HDC-/- and HDC+/+ mice, suggest-
ing a normal signal efficiency of 5-HT1A receptors in HDC
-/- mice. 
Furthermore, a single administration of citalopram produced 
an equivalent attenuation of the hypothermic response to 
8-OH-DPAT in both genotypes. These findings clearly rule out 
the possibility that HDC-/- mice are insensitive to SSRIs because 
of serotonergic system modifications. Nonetheless, compensa-
tory mechanisms in HDC-/- mice may affect behavioral responses 
to SSRIs. In the TST test though, mice acutely deprived of brain 
HA lost their sensitivity to citalopram but not to reboxetine, 
supporting our view that insensitivity to SSRIs is directly conse-
quent to the lack of HA.
As brain HA signaling seems to be involved in the acute and 
subchronic effects of citalopram, we expected citalopram to 
influence HA extraneuronal levels. Indeed, systemic administra-
tion of citalopram at the same dose effective in the TST enhanced 
cortical HA extraneuronal levels. HA increase elicited by citalo-
pram was antagonized by systemic but not intra-cortical admin-
istration of methysergide, thus suggesting the involvement of 
endogenous 5-HT. The lack of effect following intra-cortical 
administration of methysergide excludes the involvement of 
cortical 5-HT2A/2C receptors. It was previously reported that the 
TMN receives dense serotonergic projections from the raphe 
nuclei (Ericson et  al., 1989) and that 5-HT depolarizes directly 
HA neurons by activating 5-HT2C receptors (Eriksson et al., 2001). 
Taken together, these results suggest that SSRIs increase extra-
cellular levels of endogenous 5-HT in the TMN, which in turn 
impacts 5-HT2C receptors localized on HA neurons, enhances 
their firing rate, and consequently augments HA release in the 
cortex (Figure 7). In turn, HA acts on H1-receptors in the raphe 
and increases serotonergic neurons’ firing rate (Bárbara et  al., 
2002; Brown et al., 2002) (Figure 7). We believe that disruption 
of this loop in HA-deprived mice is at least in part responsible 
for the inefficacy of SSRI in the TST. Our results also indicate 
that HA signaling is necessary for citalopram to trigger CREB 
phosphorylation, as repeated administrations of citalopram 
significantly increased pCREB in the hippocampus of HDC+/+ but 
not of HDC-/- mice (Figure 7). CREB phosphorylation is one of the 
molecular mechanisms implicated in the efficacy of SSRI treat-
ment (Carlezon et al., 2005) and is required for TST response to 
citalopram, as this is completely abolished in CREB-deficient 
mice (Gur et al., 2007).
The probability of achieving and sustaining symptomatic 
remission in major depressive disorder with first-line phar-
macotherapy is approximately 30% (McIntyre, 2010); therefore, 
identifying predictors of response is a priority, as there are no bio-
markers that can reliably predict treatment efficacy. The present 
findings demonstrate that histaminergic neurotransmission is 
Figure 4. Behavioral effects of antidepressants in mice acutely deprived of brain 
histamine (HA). (A) Schematic representation of the protocol used to evaluate 
saline, citalopram, or reboxetine effects on the tail suspension test (TST) in CD-1 
mice before and after treatment with alpha-fluoromethylhistidine (α-FMHis). (B) 
Effects of treatment with citalopram and reboxetine on immobility before and 
after treatment with a-FMHis. Animals were divided into 7 groups run simul-
taneously. All data were collated. Saline, citalopram, or reboxetine was given 
i.p.  30 minutes before testing on day (D)1 and D8. On D7, mice received i.c.v. 
injections of saline or a-FMHis. Naive mice received no treatment. Represented 
are means ± SEM of 7 to 11 mice. *P < .05, **P < .01 vs corresponding saline on D1 
or D8, $$P < .01 vs same group D7 (ANOVA and Scheffe’s test).
Figure 5. Effects of citalopram on cortical histamine (HA) extraneuronal levels 
of freely moving, CD1 mice. Citalopram significantly increased HA extraneuronal 
levels immediately after its administration (n = 6). Systemic administration of 
methysergide prevented citalopram-elicited increase of HA extraneuronal lev-
els (n = 4), but not when administered in the cortex (n = 3). The arrow indicates 
the time of citalopram administration. Baseline HA extraneuronal levels were 
not detectable in alpha-fluoromethylhistidine (α-FMHis)–treated mice. In these 
animals, HA extraneuronal levels were not detectable also during citalopram 
administration (dashed line; n = 3). Represented are means ± SEM. **P < .05, 
***P < .001 vs “citalopram” and “methysergide (cortical) + citalopram”. Two-way 
ANOVA and Bonferroni’s test.
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indispensable for behavioral and neurochemical responses to 
acute administration of SSRIs. Evidence of the effects of long-
term treatments would be more convincing in terms of possible 
clinical relevance. Indeed, SSRIs quickly inhibit the serotonin 
transporter yet begin to exert an antidepressant response in 
patients during the course of 2 to 3 weeks of administration. 
Nevertheless, we may speculate that neuronal HA should be 
increased when SSRIs are taken. Single nucleotide polymor-
phism of the HA H1 receptor gene was found to play a role in 
bipolar disorder, as it was significantly associated with improve-
ments following olanzapine and fluoxetine treatment (Perlis 
et al., 2010). In addition, functional mutation in the HDC gene 
resulting in deficits of the histaminergic neuronal system has 
been linked to the mechanism and modulation of Tourette’s 
syndrome and tics (Ercan-Sencicek et al., 2010; Castellan-Baldan 
et  al., 2014). Similar genetic variations in the population may 
contribute to individual differences in antidepressant response 
and may prove good predictors of more effective treatments.
Acknowledgments
We thank Dr. M. Cowart for the synthesis of α-FMHis.
This work was supported by PRIN Grant 2009 2009ESX7T3-003 
(Italy), Compagnia di San Paolo (Italy), and CNPq 400289/2012-1 
(Brazil).
Interest Statement
None.
References
Airaksinen MS, Flugge G, Fuchs E, Panula P (1989) Histaminergic 
system in the tree shrew brain. J Comp Neurol 286:289–310.
Alexandre C, Popa D, Fabre V, Bouali S, Venault P, Lesch K, Hamon 
M, Adrien J (2006) Early life blockade of 5-hydroxytryptamine 
1A receptors normalizes sleep and depression-like behavior 
in adult knock-out mice lacking the serotonin transporter. J 
Neurosci 26:5554–5564.
Bárbara A, Aceves J, Arias-Montaño JA (2002) Histamine H1 
receptors in rat dorsal raphe nucleus: pharmacological char-
acterisation and linking to increased neuronal activity. Brain 
Res 954:247–255.
Berton O, Nestler EJ (2006a) New approaches to antidepres-
sant drug discovery: beyond monoamines. Nat Rev Neurosci 
7:137–151.
Berton O, Nestler E (2006b) New approaches to antidepressant 
drug discovery: beyond monoamines. Nat Rev Neurosci 
7:137–151.
Bezchlibnyk-Butler K, Aleksic I, Kennedy SH (2000) Citalopram-
-a review of pharmacological and clinical effects. J Psychiatry 
Neurosci 25:241–254.
Blendy J (2006) The role of CREB in depression and antidepres-
sant treatment. Biol Psychiatry 59:1144–1150.
Brown RE, Sergeeva OA, Erikson KS, Haas H L (2002) Conver-
gent excitation of dorsal raphe serotonin neurons by mul-
tiple arousal systems (orexin/hypocretin, histamine and 
noradrenaline). J Neurosci 15:8850–8859.
Carlezon W, Duman R, Nestler E (2005) The many faces of CREB. 
Trends Neurosci 28:436–445.
Cassano T, Gaetani S, Morgese M, Macheda T, Laconca L, Dipas-
quale P, Taltavull J, Shippenberg S, Cuomo V, Gobbi G (2009) 
Monoaminergic changes in locus coeruleus and dorsal raphe 
nucleus following noradrenaline depletion. Neurochem Res 
34:1417–1426.
Figure 6. Citalopram-induced CREB phosporylation is absent in histamine (HA)-deprived mice. (A) Subchronic administrations of citalopram (3 × 10 mg/kg, i.p. in 24 
hours) increased the phosphor-CREB (pCREB)/CREB ratio in the hippocampus of HDC+/+ but not of HDC-/- mice, as shown by Western-blot analysis. Shown are means ± 
SEM of 6 to 10 animals for each group; *P < .05, ##P < .01 vs citalopram-treated HDC+/+ mice. (B) Administration of 8-bromoadenosine 3’, 5’-cyclic monophosphate (8-Br-
cAMP; i.c.v., 5 µg/5 µL 30 minutes prior to sacrifice) increased the pCREB/CREB ratio in the hippocampus of mice of both genotypes. Shown are means ± SEM of 4 to 5 
mice per group (*P < .05, vs 8-Br-cAMP-treated mice, ANOVA, and Newman-Keuls post-hoc test). (C) Administration of 8-Br-cAMP significantly reduced immobility of 
mice of both genotypes in the tail suspension test (TST) (*P < .05 vs saline-treated mice; n = 8–9/group).
Figure 7. Schematic drawing illustrating the putative interactions between the 
serotonergic and histaminergic systems. Histamine (HA) neurons are localized 
exclusively in the tuberomamillary nucleus (TMN) of the posterior hypothala-
mus. The TMN receives dense serotonergic projections from the raphe nuclei 
(Ericson et  al., 1989), and 5-HT depolarizes HA neurons by activating 5-HT2C 
receptors (Eriksson et al., 2001). In turn, activation of HA H1 receptor (H1R) on 
dorsal raphe neurons increases the serotonergic neuron firing rate (Bárbara 
et al., 2002; Brown et al., 2002). The disruption of this loop in HA-deprived mice 
supposedly prevents CREB phosphorylation in the hippocampus and is respon-
sible for the inefficacy of selective serotonin reuptake inhibitors (SSRIs) in the 
tail suspension test (TST). Blockade of 5-HT2c receptors in the TMN inhibits HA 
release in the cortex. HnR, histamine receptors.
Munari et al. | 9
Castellan-Baldan L, Williams KA, Gallezot JD, Pogorelov V, Rap-
anelli M, Crowley M, Anderson GM, Loring E, Gorczyca R, Bill-
ingslea E, Wasylink S, Panza KE, Ercan-Sencicek AG, Krusong 
K, Leventhal BL, Ohtsu H, Bloch MH, Hughes ZA, Krystal JH, 
Mayes L, deAraujo I, Ding YS, State MW, Pittenger C (2014) His-
tidine decarboxylase deficiency causes tourette syndrome: 
parallel findings in humans and mice. Neuron 81:77–90.
Cenni G, Blandina P, Mackie K, Nosi D, Formigli L, Giannoni P, Bal-
lini C, DellaCorte L, Mannaioni PF, Passani MB (2006) Differen-
tial effect of cannabinoid agonists and endocannabinoids on 
histamine release from distinct regions of the rat brain. Eur J 
Neurosci 24:1633–1644.
Conti A, Cryan J, Dalvi A, Lucki I, Blendy J (2002) cAMP response 
element-binding protein is essential for the upregulation of 
brain-derived neurotrophic factor transcription, but not the 
behavioral or endocrine responses to antidepressant drugs. J 
Neurosci 22:3262–3268.
Coplan J, Gopinath S, Abdallah C, Berry B (2014) A neurobiologi-
cal hypothesis of treatment-resistant depression: mecha-
nisms for selective serotonin reuptake inhibitor non-efficacy. 
Front Behav Neurosci 8:189–196.
Cryan JF, Mombereau C, Vassout A (2005) The tail suspension 
test as a model for assessing antidepressant activity: review 
of pharmacological and genetic studies in mice. Neurosci 
Biobehav Rev 29:571–625.
Ercan-Sencicek A, Stillman A, Ghosh A, Bilguvar K, O’Roak B, 
Mason C, Abbott T, Gupta A, King R, Pauls D, Tischfield J, Hei-
man G, Singer H, Gilbert D, Hoekstra P, Morgan T, Loring E, 
Yasuno K, Fernandez T, Sanders S, Louvi A, Cho J, Mane S, Col-
angelo C, Biederer T, Lifton R, Gunel M, State M (2010) L-his-
tidine decarboxylase and Tourette’s syndrome. N Engl J Med 
362:1901–1908.
Ericson H, Blomqvist A, Köhler C (1989) Brainstem afferents to 
the tuberomammillary nucleus in the rat brain with special 
reference to monoaminergic innervation. J Comp Neurol 
281:169–192.
Eriksson KS, Stevens DR, Haas HL (2001) Serotonin excites 
tuberomammillary neurons by activation of Na(+)/Ca(2+)-
exchange. Neuropharmacology 40:345–351.
Evrard A, Malagié I, Laporte A, Boni C, Hanoun N, Trillat A, Seif 
I, DeMaeyer E, Gardier A, Hamon M, Adrien J (2002) Altered 
regulation of the 5-HT system in the brain of MAO-A knock-
out mice. Eur J Neurosci 15:841–851.
Franklin R, Paxinos G (2007) The mouse brain in stereotaxic coor-
dinates, 2nd ed. New York: Academic Press.
Garbarg M, Barbin G, Rodergras E, Schwartz JC (1980) Inhibition 
of histamine synthesis in brain by a-fluoromethylhistidine, a 
new irreversible inhibitor: in vitro and in vivo studies. J Neuro-
chem 35:1045–1052.
Goodwin G, DeSouza R, Green A (1985a) The pharmacology of 
the hypothermic response in mice to 8-hydroxy-2-(di-n-
propylamino)tetralin (8-OH-DPAT). A  model of presynaptic 
5-HT1 function. Neuropharmacology 24:1187–1194.
Goodwin G, Souza RD, Green A (1985b) The pharmacology of 
the hypothermic response in mice to 8-hydroxy-2-(di-n-
propylamino)tetralin (8-OH-DPAT). A  model of presynaptic 
5-HT1 function. Neuropharmacology 24:1187–1194.
Gray N, Milak M, DeLorenzo C, Ogden R, Y Huang, Mann J, Par-
sey R (2013) Antidepressant treatment reduces serotonin-1A 
autoreceptor binding in major depressive disorder. Biol Psy-
chiatry 74:26–31.
Gur T, Conti A, Holden J, Bechtholt A, Hill T, Lucki I, Malberg J, 
Blendy J (2007) cAMP response element-binding protein defi-
ciency allows for increased neurogenesis and a rapid onset of 
antidepressant response. J Neurosci 27:7860–7868.
Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, 
Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon 
B, Jones D, Jennum P, Jordanova A, Jönsson L, Karampampa 
K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz 
C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, 
Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer 
B, Simon R, Steinhausen H, Stovner L, Vallat J, VandenBergh 
P, vanOsP J, Xu W, Wittchen H, Jönsson B, Olesen J, Group C 
(2011) Cost of disorders of the brain in Europe. Eur Neuropsy-
chopharmacol 21:718–779.
Haas H, Sergeeva O, Selbach O (2008) Histamine in the nervous 
system. Physiol Rev 88:1183–1241.
Hajós M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH 
(2004) The selective norepinephrine reuptake inhibitor anti-
depressant reboxetine: pharmacological and clinical profile. 
CNS Drug Rev 10:23–44.
Hjorth S (1985) Hypothermia in the rat induced by the potent 
serotoninergic agent 8-OH-DPAT. J Neural Transm 61:131–135.
Kano M, Fukudo S, Tashiro A, Utsumi A, Tamura D, Itoh M, Iwata 
R, Tashiro M, Mochizuki H, Funaki Y, Kato M, Hongo M, Yanai K 
(2004) Decreased histamine H1 receptor binding in the brain 
of depressed patients. Eur J Neurosci 20:803–810.
Laitinen KS, Tuomisto L, Laitinen JT (1995) Endogenous seroto-
nin modulates histamine release in the rat hypothalamus as 
measured by in vivo microdialysis. Eur J Pharmacol 285:159–
164.
Lucki I, Dalvi A, Mayorga A (2001) Sensitivity to the effects of 
pharmacologically selective antidepressants in different 
strains of mice. Psychopharmacology 155:315–322.
Martin L, Sanders-Bush E (1982) Comparison of the pharmaco-
logical characteristics of 5 HT1 and 5 HT2 binding sites with 
those of serotonin autoreceptors which modulate serotonin 
release. Naunyn Schmiedebergs Arch Pharmacol 321:165–170.
McIntyre R (2010) When should you move beyond first-line ther-
apy for depression? J Clin Psychiatry 71:16–20.
Millan M, Gobert A, Lejeune F, Newman-Tancredi A, Rivet J-M, 
Auclair A, Peglion J-L (2001) S33005, a novel ligand of both ser-
otonin and norepinephrine transporters: I. Receptor binding, 
electrophysiological, and neurochemical profile in compari-
son with venlafaxine, reboxetine, citalopram and clomi-
pramine. J Pharmacol Exp Ther 298:565–580.
Mombereau C, Gur T, Onksen J, Blendy J (2010) Differential effects 
of acute and repeated citalopram in mouse models of anxi-
ety and depression. Int J Neuropsychopharmacol 13:321–334.
Ohtsu H, Tanaka S, Terui T, Hori Y, Makabe-Kobayashi Y, Pejler 
G, Tchougounova E, Hellman L, Gertsenstein M, Hirasawa N, 
Sakurai E, Buzas E, Kovacs P, Csaba G, Kittel A, Okada M, Hara 
M, Mar L, Numayama-Tsuruta K, Ishigaki-Suzuki S, Ohuchi K, 
Ichikawa A, Falus A, Watanabe T, Nagy A (2001) Mice lacking 
histidine decarboxylase exhibit abnormal mast cells. FEBS 
Lett 502:53–56.
O’Leary O, Bechtholt A, Crowley J, Hill T, Page M, Lucki I (2007) 
Depletion of serotonin and catecholamines block the acute 
behavioral response to different classes of antidepressant 
drugs in the mouse tail suspension test. Psychopharmacol-
ogy 192:357–371.
Parmentier R, H Ohtsu, Z Djebarra-Hannas, Valtx J-L, Watanabe T, 
Lin J-S (2002) Anatomical, physiological and pharmacological 
characteristics of histidine decarboxylase knock-out mice: 
evidence for the role of brain histamine in behavioral and 
sleep-wake control. J Neurosci 22:7695–7711.
10 | International Journal of Neuropsychopharmacology, 2015
Passani MB, Lin J-S, Hancock A, Crochet S, Blandina P (2004) The 
histamine H3 receptor as a novel therapeutic target for cog-
nitive and sleep disorders. Trends Pharmacol Sci 25:618–625.
Paxinos G, Franklin KBJ (1997) The mouse brain. New York: Aca-
demic Press.
Perlis R, Adams D, Fijal B, Sutton V, Farmen M, Breier A Houston 
JP (2010) Genetic association study of treatment response 
with olanzapine/fluoxetine combination or lamotrigine in 
bipolar I depression. J Clin Psychiatry 71:599–605.
Piñeyro G, Blier P (1999) Autoregulation of serotonin neurons: 
role in antidepressant drug action. Pharmacol Rev 51:533–591.
Seletti B, Benkelfat C, Blier P, Annable L, Gilbert F, deMontigny 
C (1995) Serotonin1A receptor activation by flesinoxan in 
humans. Body temperature and neuroendocrine responses. 
Neuropsychopharmacology 13:93–104.
Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension 
test: a new method for screening antidepressants in mice. 
Psychopharmacology 85:367–370.
Stockmeier C, Shapiro L, Dilley G, Kolli T, Friedman L, Rajkowska 
G (1998) Increase in serotonin-1A autoreceptors in the mid-
brain of suicide victims with major depression-postmortem 
evidence for decreased serotonin activity. J Neurosci 18:7394–
7401.
Takahashi K, Lin JS, Sakai K (2006) Neuronal activity of histamin-
ergic tuberomammillary neurons during wake-sleep states in 
the mouse. J Neurosci 26:10292–10298.
Watanabe T, Taguchi Y, Hayashi H, Tanaka J, Shiosaka S, Tohy-
ama M, Kubota H, Terano Y, Wada H (1983) Evidence for 
the presence of a histaminergic neuron system in the rat 
brain:an immunohistochemical analysis. Neurosci Lett 
39:249–254.
Wong E, Sonders M, Amara S, Tinholt P, Piercey M, Hoffmann 
W, Hyslop D, Franklin S, Porsolt R, Bonsignori A, Carfagna N, 
McArthur R (2000) Reboxetine: a pharmacologically potent, 
selective, and specific norepinephrine reuptake inhibitor. Biol 
Psychiatry 47:818–829.
Yanai K, Tashiro M (2007) The physiological and pathophysi-
ological roles of neuronal histamine: an insight from human 
positron emission tomography studies. Pharmacol Ther 
113:1–15.
